Matrine induces RIP3-dependent necroptosis in cholangiocarcinoma cells.
The development of acquired resistance to pro-apoptotic antitumor agents is a major impediment to the cure of cholangiocarcinoma (CCA). Antitumor drugs inducing non-apoptotic cell death are considered as a new approach to overcome such drug resistance. Here, we reported for the first time that matrine-induced necroptosis in CCA cell lines, differing from its classical role to induce apoptosis in many other kinds of cancer cells. CCA cells under matrine treatment exhibited typical necrosis-like but not apoptotic morphologic change. These matrine-induced morphologic change and cell death in CCA cells were greatly attenuated by necroptosis inhibitor necrostatin-1, but not apoptosis inhibitor z-VAD-fmk. Unlike many cancer cells with negative receptor-interacting protein 3 (RIP3) expression, moderate expression of RIP3 in CCA cells was observed and was required for matrine to induce necroptosis, which was switched to apoptosis after knocking down endogenous RIP3. Moreover, matrine could increase RIP3 expression level, which may facilitate the necroptosis process. Translocation of mixed lineage kinase-domain like (MLKL) from cytoplasm to plasma membrane as a downstream event of RIP3, as well as the increased production of reactive oxygen species (ROS) by RIP3/MLKL, was critical for matrine to induce necroptosis. In clinical study, we found RIP3 was lower but still moderately expressed in most CCA tissue samples compared with adjacent normal tissues. Taken together, we identified matrine as a necroptosis inducer in CCA by enhancing RIP3 expression and the following RIP3/MLKL/ROS signaling pathway, which provided new individualized strategies based on RIP3 expression to overcome chemoresistance in CCA therapy.
Cancer Research Center, Xiamen University Medical College , Xiamen 361102, China.
Beibei
B
Xu
Cancer Research Center, Xiamen University Medical College , Xiamen 361102, China.
Minying
M
Xu
Cancer Research Center, Xiamen University Medical College , Xiamen 361102, China.
Yuan
Y
Tian
Cancer Research Center, Xiamen University Medical College , Xiamen 361102, China.
Qiang
Q
Yu
Cancer Research Center, Xiamen University Medical College , Xiamen 361102, China.
Yujie
Y
Zhao
Cancer Research Center, Xiamen University Medical College , Xiamen 361102, China.
Xiong
X
Chen
Cancer Research Center, Xiamen University Medical College , Xiamen 361102, China.
Panying
P
Mi
Cancer Research Center, Xiamen University Medical College , Xiamen 361102, China.
Hanwei
H
Cao
Department of Basic Medicine, Xiamen University Medical College , Xiamen 361102, China.
Bing
B
Zhang
Cancer Research Center, Xiamen University Medical College , Xiamen 361102, China.
Gang
G
Song
Cancer Research Center, Xiamen University Medical College , Xiamen 361102, China.
Yan-Yan
YY
Zhan
Cancer Research Center, Xiamen University Medical College , Xiamen 361102, China.
Tianhui
T
Hu